BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35352020)

  • 21. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
    Urology; 1999 Oct; 54(4):656-61. PubMed ID: 10510924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
    de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
    Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry.
    Silva CL; Passos M; Câmara JS
    Br J Cancer; 2011 Dec; 105(12):1894-904. PubMed ID: 22085842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.
    Heicappell R; Schostak M; Müller M; Miller K
    Scand J Clin Lab Invest; 2000 Jul; 60(4):275-82. PubMed ID: 10943597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
    Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
    Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
    Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
    Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
    Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
    Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
    Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
    Kavalieris L; O'Sullivan P; Frampton C; Guilford P; Darling D; Jacobson E; Suttie J; Raman JD; Shariat SF; Lotan Y
    J Urol; 2017 Jun; 197(6):1419-1426. PubMed ID: 27986532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.
    Boman H; Hedelin H; Jacobsson S; Holmäng S
    J Urol; 2002 Nov; 168(5):1955-9. PubMed ID: 12394684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
    Lotan Y; Black PC; Caba L; Chang SS; Cookson MS; Daneshmand S; Kamat AM; McKiernan JM; Pruthi RS; Ritch CR; Steinberg GD; Svatek RS; Zwarthoff EC
    Eur Urol Oncol; 2018 Aug; 1(3):223-230. PubMed ID: 31102625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.
    Mbeutcha A; Lucca I; Mathieu R; Lotan Y; Shariat SF
    Urol Clin North Am; 2016 Feb; 43(1):47-62. PubMed ID: 26614028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Volatile organic compounds as biomarkers of bladder cancer: Sensitivity and specificity using trained sniffer dogs.
    Willis CM; Britton LE; Harris R; Wallace J; Guest CM
    Cancer Biomark; 2010-2011; 8(3):145-53. PubMed ID: 22012770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.